stockrowXeris Biopharma Holdings, Inc.
XERS Healthcare Drug Manufacturers Specialty & Generic
Xeris Biopharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $291.8 million, up 43.7% from fiscal 2024.
- Revenue
- +44.2%
- EPS
- +1,479.0%
- Free cash flow
- +93.2%
- Total debt
- −13.6%
Quarter to September 2026, against a year earlier
Follow XERS
Alert me
Xeris Biopharma Holdings, Inc. (XERS) Net income
Xeris Biopharma Holdings, Inc.'s net income for fiscal 2025 was $554.0K, compared with −$54.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$6.5M. Over the past ten years it has ranged from −$125.6M (fiscal 2019) to $554.0K (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 4 consecutive fiscal years. Xeris Biopharma Holdings, Inc. ranks 39th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $554.0K | — |
| FY2024 | −$54.8M | — |
| FY2023 | −$62.3M | — |
| FY2022 | −$94.7M | — |
| FY2021 | −$122.7M | — |
| FY2020 | −$91.1M | — |
| FY2019 | −$125.6M | — |
| FY2018 | −$60.1M | — |
| FY2017 | −$26.6M | — |
| FY2016 | −$13.2M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $11.3M | — |
| Jun 2026 | −$31.1M | — |
| Mar 2026 | $2.2M | (79.84%) |
| Dec 2025 | $11.1M | 1,684.38% |
| 35 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| HCM HUTCHMED (China) Limited Sponsored ADR compare | $967.7M |
| PBH Prestige Consumer Healthcare Inc. compare | $155.1M |
| XERS Xeris Biopharma Holdings, Inc. | −$6.5M |
| RGC Regencell Bioscience Holdings Limited compare | −$14.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$152.1M |
| ALVO Alvotech compare | −$179.6M |
| BCRX BioCryst Pharmaceuticals, Inc. compare | −$359.7M |
| TRLV Trulieve Cannabis Corp. compare | −$446.6M |
| PRGO Perrigo Company plc compare | −$1.8B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on XERS
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement